{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T17:22:21Z","timestamp":1780939341319,"version":"3.54.1"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","license":[{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>Although there is a lack of data in trimethoprim-sulfamethoxazole (TMP-SMX) serum monitoring utility for invasive nocardial infections, therapeutic drug monitoring is widely used to optimize dosing and avoid adverse reactions that may cause treatment interruption.<\/jats:p>\n            <jats:p>We retrospectively reviewed all adults who received TMP-SMX to treat nocardial brain abscess and had SMX serum level testing from 2010 to 2020.<\/jats:p>\n            <jats:p>Twenty-two patients received treatment with TMP-SMX for <jats:italic toggle=\"yes\">Nocardia<\/jats:italic> species brain abscess and 16 (72.7%) had a reported SMX level, with a median patient age of 65.5\u200ayears (interquartile range, IQR 59.5\u201372.5). Compared to those who did not have a documented SMX serum level, patients with SMX levels had a shorter median course of TMP-SMX treatment (322\u200adays [IQR 188\u2013365] vs. 365 [IQR 224\u2013365]; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.31) and higher therapeutic induction dose (10 [62.5%] vs. 3 [50%]; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.92). Similarly, they were more frequently on hemodialysis (3 [13.6%] vs. 1 [4.5%]; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a&gt;\u200a.99). The median peak level was 158.5 (IQR 120\u2013218)\u200a\u03bcg\/mL, collected at 2\u200ahours (75%) post-administration in the induction phase (81.3%). Patients with documented SMX levels had fewer reported drug toxicity (5 [31.3%] vs. 4 [66.7%]; <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.1) than those without SMX levels. Among the five patients who reported TMP-SMX-related toxicity, 4 (80%) had an SMX peak level &gt;150\u200a\u03bcg\/mL. There was no difference in the cure, relapse, and death rates among the two groups.<\/jats:p>\n            <jats:p>While SMX level was not associated with <jats:italic toggle=\"yes\">Nocardia<\/jats:italic> species brain abscess cure rates and mortality, most patients with SMX peak &gt;150\u200a\u03bcg\/mL experienced drug toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028951","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T13:04:22Z","timestamp":1646399062000},"page":"e28951","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Observational study of the clinical utility of sulfamethoxazole serum level monitoring in the treatment of brain abscesses due to Nocardia species"],"prefix":"10.1097","volume":"101","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0976-7905","authenticated-orcid":false,"given":"Cristina","family":"Corsini Campioli","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Abu Saleh","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic College of Medicine and Science, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin C.","family":"Mara","sequence":"additional","affiliation":[{"name":"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina G.","family":"Rivera","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,3,4]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1212\/WNL.0000000000000172","article-title":"Clinical characteristics and outcome of brain abscess Systematic review and meta-analysis","volume":"82","author":"Brouwer","year":"2014","journal-title":"Neurology"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1752-1947-7-103","article-title":"Sulfonamide resistance in a disseminated infection caused by Nocardia wallacei: a case report","volume":"7","author":"Cassir","year":"2013","journal-title":"J Med Case Rep"},{"key":"R3-20250504","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01868-19","article-title":"Retrospective analysis of antimicrobial susceptibility profiles of Nocardia species from a tertiary hospital and reference laboratory, 2011 to 2017","volume":"64","author":"Hamdi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood-brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"R5-20250504","first-page":"1064","article-title":"[Diffusion of tetroxoprim and sulfadiazine in the cerebrospinal fluid of neurosurgery patients]","volume":"102","author":"Albert","year":"1984","journal-title":"Fortschr Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.ejim.2013.05.004","article-title":"Nocardiosis: a 15-year experience in a tertiary medical center in Israel","volume":"24","author":"Rosman","year":"2013","journal-title":"Eur J Intern Med"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1056\/NEJM199009203231202","article-title":"Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone","volume":"323","author":"Medina","year":"1990","journal-title":"N Engl J Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"ofaa112","DOI":"10.1093\/ofid\/ofaa112","article-title":"Low-dose TMP-SMX in the treatment of Pneumocystis jirovecii pneumonia: a systematic review and meta-analysis","volume":"7","author":"Butler-Laporte","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"ofab067","DOI":"10.1093\/ofid\/ofab067","article-title":"Clinical presentation, management, and outcomes of patients with brain abscess due to Nocardia species","volume":"8","author":"Corsini Campioli","year":"2021","journal-title":"Open Forum Infectious Diseases"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.mayocp.2011.11.016","article-title":"Nocardiosis: updates and clinical overview","volume":"87","author":"Wilson","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"R31","DOI":"10.1186\/cc5713","article-title":"Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury","volume":"11","author":"Mehta","year":"2007","journal-title":"Crit Care"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1093\/clinids\/4.2.426","article-title":"Adverse reactions to trimethoprim-sulfamethoxazole in hospitalized patients","volume":"4","author":"Jick","year":"1982","journal-title":"Rev Infect Dis"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1093\/jac\/dks030","article-title":"Acute kidney injury associated with trimethoprim\/sulfamethoxazole","volume":"67","author":"Fraser","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00019048-199507000-00011","article-title":"Evaluation of therapy for Nocardia asteroides complex infections","volume":"4","author":"Mcneil","year":"1995","journal-title":"Infect Dis Clin Prac"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1177\/106002808902300903","article-title":"Clinical use of trimethoprim\/sulfamethoxazole during renal dysfunction","volume":"23","author":"Paap","year":"1989","journal-title":"DICP"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1128\/AAC.39.1.28","article-title":"Pharmacokinetics of trimethoprim-sulfamethoxazole in critically ill and non-critically ill AIDS patients","volume":"39","author":"Chin","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/BF01728888","article-title":"Variability of serum concentrations of trimethoprim and sulfamethoxazole during high dose therapy","volume":"21","author":"Blaser","year":"1993","journal-title":"Infection"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1128\/AAC.39.12.2661","article-title":"Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia","volume":"39","author":"Joos","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/FTD.0000000000000282","article-title":"Relationship of sulfamethoxazole therapeutic drug monitoring to clinical efficacy and toxicity: a retrospective cohort study","volume":"38","author":"Ice","year":"2016","journal-title":"Ther Drug Monit"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/MD.0000000000000012","article-title":"Nocardiosis of the central nervous system: experience from a general hospital and review of 84 cases from the literature","volume":"93","author":"Anagnostou","year":"2014","journal-title":"Medicine (Baltimore)"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1365-2710.1998.00152.x","article-title":"Drug monitoring during the treatment of AIDS-associated Pneumocystis carinii pneumonia with trimethoprim-sulfamethoxazole","volume":"23","author":"Klinker","year":"1998","journal-title":"J Clin Pharm Ther"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.curtheres.2014.08.003","article-title":"Serum peak sulfamethoxazole concentrations demonstrate difficulty in achieving a target range: a retrospective cohort study","volume":"76","author":"Dao","year":"2014","journal-title":"Curr Ther Res Clin Exp"},{"issue":"(Suppl 5)","key":"R24-20250504","doi-asserted-by":"crossref","first-page":"S227","DOI":"10.1007\/BF01643193","article-title":"Adverse reactions to Bactrim\u2014a retrospective view","volume":"15","author":"Hell","year":"1987","journal-title":"Infection"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028951","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:06:09Z","timestamp":1746331569000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,4]]},"references-count":23,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028951","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,4]]},"assertion":[{"value":"2021-10-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}